|
|
 Previous Article | Table of Contents | Next Article 
Blood, 15 June 2002, Vol. 99, No. 12, pp. 4276-4282
REVIEW ARTICLE
Autologous stem cell transplantation for primary systemic
amyloidosis
Raymond L. Comenzo and
Morie A. Gertz
From the Hematology Service, Department of Medicine,
Memorial Sloan-Kettering Cancer Center, New York, NY; and the Division
of Hematology, Mayo Clinic, Rochester, MN.
High-dose melphalan with autologous blood stem cell transplantation
(SCT) can reverse the disease process in selected patients with primary
systemic amyloidosis (AL); however, SCT for AL remains controversial
because of the treatment-related mortality in patients with cardiac and
multisystem organ involvement. In this review, we briefly discuss
recent advances in AL, such as the free light-chain assay and the role
of immunoglobulin light-chain variable region germline genes in the
disease, and then we discuss the current status of SCT for AL with
emphases on patient selection, approaches to stem cell
mobilization, and peri-SCT management. It is clear that patients with
AL who have advanced amyloid cardiomyopathy or more than 2 major
viscera involved with disease are poor candidates for SCT. Therefore,
the importance of patient selection cannot be overemphasized, and
patients with 1 or 2 involved organs or with early cardiac involvement
are usually appropriate candidates for SCT. Because the toxicity of
melphalan is dose-related and survival with AL may be
age-related, patient age and the extent of organ involvement can
provide a basis for patient stratification. We discuss such a
risk-adapted approach to melphalan dosing in detail and conclude with a
brief overview of current research using SCT to treat patients with AL.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
P. Ronco and P. Aucouturier
Renal involvement in AL amyloidosis: the facts, the promise and the hope
Nephrol. Dial. Transplant.,
October 1, 2009;
24(10):
2967 - 2969.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. V. Kristen, F.-U. Sack, S. O. Schonland, U. Hegenbart, B. M. Helmke, A. Koch, P. A. Schnabel, C. Rocken, S. Hardt, A. Remppis, et al.
Staged heart transplantation and chemotherapy as a treatment option in patients with severe cardiac light-chain amyloidosis
Eur J Heart Fail,
October 1, 2009;
11(10):
1014 - 1020.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. E. Reece, V. Sanchorawala, U. Hegenbart, G. Merlini, G. Palladini, J.-P. Fermand, R. A. Vescio, X. Liu, Y. A. Elsayed, A. Cakana, et al.
Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study
Blood,
August 20, 2009;
114(8):
1489 - 1497.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Solomon, S. D. Macy, C. Wooliver, D. T. Weiss, and P. Westermark
Splenic plasma cells can serve as a source of amyloidogenic light chains
Blood,
February 12, 2009;
113(7):
1501 - 1503.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Mignot, F. Bridoux, A. Thierry, S. Varnous, M. Pujo, A. Delcourt, J. M. Gombert, J.-M. Goujon, F. Favreau, G. Touchard, et al.
Successful heart transplantation following melphalan plus dexamethasone therapy in systemic AL amyloidosis
Haematologica,
March 1, 2008;
93(3):
e32 - e35.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kumar, A. Dispenzieri, M. A. Gertz, J. Mehta, H. J. Lachmann, A. D. Wechalekar, J. D. Gillmore, H. M. Lokhorst, B. P.C. Hazenberg, A. Croockewit, et al.
High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis
N. Engl. J. Med.,
January 3, 2008;
358(1):
91 - 93.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. B. Selvanayagam, P. N. Hawkins, B. Paul, S. G. Myerson, and S. Neubauer
Evaluation and Management of the Cardiac Amyloidosis
J. Am. Coll. Cardiol.,
November 27, 2007;
50(22):
2101 - 2110.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Kastritis, A. Anagnostopoulos, M. Roussou, S. Toumanidis, C. Pamboukas, M. Migkou, A. Tassidou, I. Xilouri, S. Delibasi, E. Psimenou, et al.
Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone
Haematologica,
October 1, 2007;
92(10):
1351 - 1358.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Jaccard, P. Moreau, V. Leblond, X. Leleu, L. Benboubker, O. Hermine, C. Recher, B. Asli, B. Lioure, B. Royer, et al.
High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis
N. Engl. J. Med.,
September 13, 2007;
357(11):
1083 - 1093.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. V. Kristen, J. B. Perz, S. O. Schonland, U. Hegenbart, P. A. Schnabel, J. H. Kristen, H. Goldschmidt, H. A. Katus, and T. J. Dengler
Non-invasive predictors of survival in cardiac amyloidosis
Eur J Heart Fail,
June 1, 2007;
9(6-7):
617 - 624.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. D. Wechalekar, H. J. B. Goodman, H. J. Lachmann, M. Offer, P. N. Hawkins, and J. D. Gillmore
Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis
Blood,
January 15, 2007;
109(2):
457 - 464.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. M. Dember
Amyloidosis-Associated Kidney Disease
J. Am. Soc. Nephrol.,
December 1, 2006;
17(12):
3458 - 3471.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Comenzo, H. Hassoun, L. Reich, N. Collins, A. Nuta, X. Chen, P. Zhou, B. Clark, J. Teruya-Feldstein, M. Fleisher, et al.
Mobilization of Blood Stem Cells with G-CSF in Systemic Light-Chain Amyloidosis: Dominant Organ Involvement Significantly Affects Stem Cell Collection.
Blood (ASH Annual Meeting Abstracts),
November 16, 2006;
108(11):
3087 - 3087.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Palladini, V. Perfetti, P. Russo, F. Lavatelli, M. Nuvolone, L. Obici, and G. Merlini
Early Harvest Followed by Melphalan-Dexamethasone and Second-Line Autologous Stem Cell Transplantation in AL Amyloidosis.
Blood (ASH Annual Meeting Abstracts),
November 16, 2006;
108(11):
5449 - 5449.
[Abstract]
[PDF]
|
|
|
|
|
|
|
H J Lachmann and P N Hawkins
Amyloidosis and the lung
Chronic Respiratory Disease,
November 1, 2006;
3(4):
203 - 214.
[Abstract]
[PDF]
|
|
|
|
|
|
|
V. Sanchorawala
Light-Chain (AL) Amyloidosis: Diagnosis and Treatment
Clin. J. Am. Soc. Nephrol.,
November 1, 2006;
1(6):
1331 - 1341.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Merlini and M. J. Stone
Dangerous small B-cell clones
Blood,
October 15, 2006;
108(8):
2520 - 2530.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. P. Sviggum, M. D. P. Davis, S. V. Rajkumar, and A. Dispenzieri
Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma.
Arch Dermatol,
October 1, 2006;
142(10):
1298 - 1302.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Solomon, C. L. Murphy, P. Westermark, and R. L. Comenzo
Misclassification of amyloidosis is unwarranted.
Blood,
July 15, 2006;
108(2):
776 - 777.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. H. Vesole, W. S. Perez, M. Akasheh, C. Boudreau, D. E. Reece, C. N. Bredeson, and Plasma Cell Disorders Working Committee of the Cen
High-Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation for Patients With Primary Systemic Amyloidosis: A Center for International Blood and Marrow Transplant Research Study
Mayo Clin. Proc.,
July 1, 2006;
81(7):
880 - 888.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Palladini, F. Lavatelli, P. Russo, S. Perlini, V. Perfetti, T. Bosoni, L. Obici, A. R. Bradwell, G. M. D'Eril, R. Fogari, et al.
Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL
Blood,
May 15, 2006;
107(10):
3854 - 3858.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. V. Rajkumar, A. Dispenzieri, and R. A. Kyle
Monoclonal Gammopathy of Undetermined Significance, Waldenstrom Macroglobulinemia, AL Amyloidosis, and Related Plasma Cell Disorders: Diagnosis and Treatment
Mayo Clin. Proc.,
May 1, 2006;
81(5):
693 - 703.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. Comenzo, P. Zhou, M. Fleisher, B. Clark, and J. Teruya-Feldstein
Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins
Blood,
May 1, 2006;
107(9):
3489 - 3491.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. O. Schonland, H. Lokhorst, A. Buzyn, V. Leblond, U. Hegenbart, G. Bandini, A. Campbell, E. Carreras, A. Ferrant, L. Grommisch, et al.
Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: a report from the European Group for Blood and Marrow Transplantation
Blood,
March 15, 2006;
107(6):
2578 - 2584.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D. Gillmore, H. J. Goodman, H. J. Lachmann, M. Offer, A. D. Wechalekar, J. Joshi, M. B. Pepys, and P. N. Hawkins
Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis
Blood,
February 1, 2006;
107(3):
1227 - 1229.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. Comenzo
Light chains ahoy: pirating Thal/Dex for AL too
Blood,
April 1, 2005;
105(7):
2625 - 2625.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Palladini, V. Perfetti, S. Perlini, L. Obici, F. Lavatelli, R. Caccialanza, R. Invernizzi, B. Comotti, and G. Merlini
The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL)
Blood,
April 1, 2005;
105(7):
2949 - 2951.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. F. Porrata, M. A. Gertz, M. R. Litzow, M. Q. Lacy, A. Dispenzieri, D. J. Inwards, S. M. Ansell, I. N.M. Micallef, D. A. Gastineau, M. Elliott, et al.
Early Lymphocyte Recovery Predicts Superior Survival after Autologous Hematopoietic Stem Cell Transplantation for Patients with Primary Systemic Amyloidosis
Clin. Cancer Res.,
February 1, 2005;
11(3):
1210 - 1218.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Y. Kwong and R. H. Falk
Cardiovascular Magnetic Resonance in Cardiac Amyloidosis
Circulation,
January 18, 2005;
111(2):
122 - 124.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Dispenzieri, M. A. Gertz, R. A. Kyle, M. Q. Lacy, M. F. Burritt, T. M. Therneau, J. P. McConnell, M. R. Litzow, D. A. Gastineau, A. Tefferi, et al.
Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation
Blood,
September 15, 2004;
104(6):
1881 - 1887.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Dispenzieri, R. A. Kyle, M. Q. Lacy, T. M. Therneau, D. R. Larson, M. F. Plevak, S. V. Rajkumar, R. Fonseca, P. R. Greipp, T. E. Witzig, et al.
Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study
Blood,
May 15, 2004;
103(10):
3960 - 3963.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Palladini, V. Perfetti, L. Obici, R. Caccialanza, A. Semino, F. Adami, G. Cavallero, R. Rustichelli, G. Virga, and G. Merlini
Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation
Blood,
April 15, 2004;
103(8):
2936 - 2938.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Gertz, G. Merlini, and S. P. Treon
Amyloidosis and Waldenstrom's Macroglobulinemia
Hematology,
January 1, 2004;
2004(1):
257 - 282.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Snanoudj, M.-F. Mamzer-Bruneel, O. Hermine, J.-P. Grunfeld, and D. Chauveau
Recovery of acute renal failure and nephrotic syndrome following autologous stem cell transplantation for primary (AL) amyloidosis
Nephrol. Dial. Transplant.,
October 1, 2003;
18(10):
2175 - 2177.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Berk, J. Keane, D. C. Seldin, V. Sanchorawala, J. Koyama, L. M. Dember, and R. H. Falk
Persistent Pleural Effusions in Primary Systemic Amyloidosis: Etiology and Prognosis
Chest,
September 1, 2003;
124(3):
969 - 977.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Solomon, D. T. Weiss, and J. S. Wall
Therapeutic Potential of Chimeric Amyloid-reactive Monoclonal Antibody 11-1F4
Clin. Cancer Res.,
September 1, 2003;
9(10):
3831s - 3838s.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
A. J. Peniket, T. J. Littlewood, and C. G. Winearls
The radical treatment of paraprotein disorders affecting the kidney
Nephrol. Dial. Transplant.,
August 1, 2003;
18(8):
1431 - 1434.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Peniket, T. J. Littlewood, and C. G. Winearls
The radical treatment of paraprotein disorders affecting the kidney
Nephrol. Dial. Transplant.,
August 1, 2003;
18(88):
1431 - 1434.
[Full Text]
|
|
|
|
|
|
|
R. Rysava, M. Merta, I. Spicka, and V. Tesar
Current therapeutic possibilities in primary and secondary amyloidosis and our experience with 31 patients
Nephrol. Dial. Transplant.,
July 1, 2003;
18(90005):
v38 - 40.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Gertz
Diagnosing Primary Amyloidosis
Mayo Clin. Proc.,
December 1, 2002;
77(12):
1278 - 1279.
[PDF]
|
|
|
|
|
